US-based biotechnology company Therini Bio has reported positive results from a Phase Ia trial of THN391, a potential ...

Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson's Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+ Presenter: Joanne ...

The U.S. Food and Drug Administration notified consumers of a recall for a “healthy aging” supplement.The recall, initiated due to an undeclared allergen, has been officially labeled a Class 1 recall, ...